TG Therapeutics | TGTX - Les Charges D'Exploitation





Les Charges D'Exploitation Changement Date
AbbVie USD 10.52B 258M 2026-09
Alaunos Therapeutics USD 952K 60K 2026-06
Amgen USD 5.69B 6B 2026-09
Ardelyx USD 133.3M 6.04M 2026-06
Arrowhead Research USD 245.35M 30.35M 2026-06
Bayer EUR 9.92B 121M 2026-09
Biogen USD 2.32B 663.6M 2026-09
Corcept Therapeutics USD 225.75M 10.9M 2026-09
Curis USD 11.52M 2.5M 2026-03
Gilead Sciences USD 13.04B 9.09B 2026-09
J&J USD 18.93B 1.09B 2026-09
Karyopharm Therapeutics USD 61.83M 9.9M 2026-03
Novartis USD 9.88B 325M 2026-09
Novavax USD 126.2M 23.62M 2025-12
PTC Therapeutics USD 211.54M 15.12M 2026-06
Puma Biotechnology USD 49.26M 3.2M 2024-06
Regeneron Pharmaceuticals USD 33.5B 1.79B 2026-09
Roche Holding CHF 18.9B 2.12B 2026-06
TG Therapeutics USD 174.04M 44.62M 2026-09
Verastem USD 63.57M 4.56M 2026-03
Vertex Pharmaceuticals USD 2.18B 118.2M 2026-09